Cat. No.: HY-156819

Zoldonrasib

(Synonyms: RMC-9805; KRAS G12D inhibitor 18)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer.

For research use only. We do not sell to patients.

Purity: 99.52%
CAS No.: 3034802-05-3
Formula: C₆₃H₈₈F₃N₁₁O₇
Molecular Weight:1168.44

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Zoldonrasib Chemical Structure

CAS No.: 3034802-05-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

KRAS(G12D)

All Ras Isoforms :

In Vitro

Zoldonrasib (RMC-9805) (100 nM; 48 h) inhibits the production of CXCL1, GM-CSF and decreases the production of CXCL10, CCL17 in eCT26 (KRASG12D/G12D) cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Zoldonrasib (RMC-9805) (100 mg/kg; po; once daily for 4-8 days) shows antitumor activity in KRAS G12D xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice^[2]
Dosage:

100 mg/kg
Administration:

PO; once daily for 4-8 days
Result:

Decreased the level of myeloid cells, such as mMDSC, gMDSC, M2 TAMS, increased the level of cytotoxic T cells including CD3e⁺, CD4⁺, CD8⁺ T cells.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 3034802-05-3
Appearance Solid
Molecular Weight 1168.44
Formula C₆₃H₈₈F₃N₁₁O₇
Color White to yellow
SMILES

O=C([C@H]1NN(C([C@@H](NC([C@@H](N2C[C@]3(CN(C([C@@H]4N(C)[C@@H]4C5CC5)=O)CC3)CC2)C6CCCC6)=O)C[C@H]7CN8CCO7)=O)CCC1)OCC(C)(C)CC9=[C@@]([C@@]%10=C([C@@H](OC)C)N=CC(N%11CCN(C%12CC%12)CC%11)=C%10)N(CC(F)(F)F)C%13=C9C=C8C=C%13
Synonyms

RMC-9805; KRAS G12D inhibitor 18
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All In Vivo Efficacy StudyWBBio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. [Abstract]

2026 Feb;650(8102):748-758. PMID: 41286180

Zoldonrasib purchased from MedChemExpress. Usage Cited in: Nature. 2026 Feb;650(8102):748-758. [Abstract]

Liver metastatic burden in AKPT treated from 7 days post-transplantation and continued for 21 days. RMC9805 (100 mg/kg, oral, daily, 3 weeks) versus RMC6236 versus combined RMC9805–RMC6236 versus vehicle are shown.
Mol Cell

Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. [Abstract]

2026 Jan 8;86(1):60-77.e7. PMID: 41475344

Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]

Western blotting of AURKA, SRSF1, MYC, phosphorylated and total ERK1/2 (p-ERK and t-ERK, respectively), and VINC from SUIT2 parental cells and SUIT2 RMC-9805-resistant cells. Cells were either treated with DMSO, RMC-9805 (1 μM), or RMC-9805 (1 μM) + SC or ASO-A (65 nM) for 48 h.

Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]

Parental cells were sensitive to RMC-9805 (1 μM, 48 h), showing reduced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation (p-ERK), drug-resistant cells, on the other hand, maintain mitogen-activated protein kinase (MAPK) signaling.

Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]

Parental cells were sensitive to RMC-9805 (1 μM, 48 h), resulting in decreased cell viability, while drug-resistant cells maintained cell viability.
Carcinogenesis

Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer. [Abstract]

2025 Apr 3;46(2):bgaf036. PMID: 40755231
bioRxiv

2026 Mar 12.
bioRxiv

2025 April 15.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (85.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.8558 mL

4.2792 mL

8.5584 mL

5 mM

0.1712 mL

0.8558 mL

1.7117 mL

10 mM

0.0856 mL

0.4279 mL

0.8558 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13

[2]. Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475

[3]. John E. Knox, et al. Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.8558 mL	4.2792 mL	8.5584 mL	21.3961 mL
	5 mM	0.1712 mL	0.8558 mL	1.7117 mL	4.2792 mL
	10 mM	0.0856 mL	0.4279 mL	0.8558 mL	2.1396 mL
	15 mM	0.0571 mL	0.2853 mL	0.5706 mL	1.4264 mL
	20 mM	0.0428 mL	0.2140 mL	0.4279 mL	1.0698 mL
	25 mM	0.0342 mL	0.1712 mL	0.3423 mL	0.8558 mL
	30 mM	0.0285 mL	0.1426 mL	0.2853 mL	0.7132 mL
	40 mM	0.0214 mL	0.1070 mL	0.2140 mL	0.5349 mL
	50 mM	0.0171 mL	0.0856 mL	0.1712 mL	0.4279 mL
	60 mM	0.0143 mL	0.0713 mL	0.1426 mL	0.3566 mL
	80 mM	0.0107 mL	0.0535 mL	0.1070 mL	0.2675 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Zoldonrasib

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Kinase Inhibitor Library Mini

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

KRAS Targeted Compound Library

Publications Citing Use of MedChemExpress (MCE) Zoldonrasib

All Ras Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Zoldonrasib Related Classifications

HY-156819 Related Classifications